In the current analysis, the lowest mortality relative to placebo was associated with the use of trimodulin in sCAP patient subsets with high CRP, low IgM, and/or lymphopenia and/or high NLR. The gene discussed is CRP; the disease is syringocystadenoma papilliferum.